Improving Cardiovascular Disease Outcomes Challenge

Our deep and long-standing commitment to cardiovascular disease began more than 60 years ago. Today, we are evaluating multiple novel agents to address the needs of patients with serious cardiovascular conditions. Our research is focused on cardiovascular diseases with high unmet needs such as arterial thrombosis, defined subsets of heart failure and cardiomyopathy.

This is an electronic Request-for-Proposals Challenge; the Entrant will only need to submit a written proposal to be evaluated by BMS with the goal of establishing a collaborative partnership.

 

OVERVIEW

Bristol Myers Squibb (BMS) is seeking digital health startup companies or small- or medium-sized enterprises with mid- to late-stage technologies that could create a world with better outcomes for those living with cardiovascular disease. BMS takes its commitment to economic, social and environmental sustainability seriously, and extends this expectation to its partners and suppliers. As a responsible corporate citizen, we seek to actively improve the health of the communities where we live, work and serve. Around the globe, we promote health equity and seek to promote the health outcomes of populations disproportionately affected by serious disease. We believe our diverse and inclusive culture supports better outcomes for all patients and we seek diversity in all aspects of our business.

This is an electronic Request-for-Proposals Challenge. The Entrant will submit a preliminary proposal (including supporting non-confidential information and contact details) to be evaluated by BMS with the goal of presenting a solution that addresses cardiovascular diseases, as further detailed below. Upon completion of the evaluation, BMS may contact selected Entrants directly to select up to five finalists, who will be invited to present live at their own expense during the HLTH Conference (www.HLTH.com) in Las Vegas, Nevada on November 15, 2022.

Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on October 31, 2022. 

Late submissions will not be considered.

 

THE CHALLENGE

How can healthcare equity be addressed by leveraging technology for all three CV diseases mentioned below, keeping in mind that access to health technology, trust, and health literacy are all critical for improving health outcomes in Medically Underserved Communities (MUC)?

Find solutions for the following areas in the CV patient journey:

1. Diagnosis of CV diseases such as obstructive hypertrophic cardiomyopathy (oHCM), AFib, heart failure
2. Health Equity – what advancements are there in technology to address MUC as it relates to the diagnosis of CV disease?

 

THE OPPORTUNITY

• Up to five finalists will be invited to participate in a live pitching event at the HLTH conference in Las Vegas, Nevada on November 15, 2022. Travel and accommodations are not included.
• For more information about HLTH please visit their website: https://www.hlth.com/
• The Award: Opportunity to pilot with BMS and to meet with the Bio + Health investing team at Andreessen Horowitz (a16z). The team at a16z Bio + Health backs bold entrepreneurs who are engineering biology and reimagining healthcare.